EUVIMEDOpdag EUVIMED
Beobachtungsstudie

Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice

Jian Zhou, Yuan Yuan, Yanhua Liu, Mengyang Chu, Huan Liu, Qian Liu, Rui Wang, Shuai Shao, Gang Wang, Chen Yu iD

Experimental Dermatology · 2024

DOI: 10.1111/exd.14890 ↗

At a glance

Beobachtungsstudie in Experimental Dermatology, 2024. Written by Jian Zhou and 9 co-authors. Institution: Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, P. R. China. Major MEDLINE topics: Antibodies, Monoclonal, Psoriasis, Antibodies, Monoclonal, Humanized. Cited 15 times so far (Crossref); 29 references. Funded by: National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

A number of randomized controlled trials and real‐world studies have demonstrated the effectiveness and safety of secukinumab in the treatment of moderate to severe psoriasis, whereas data on a large cohort of Chinese patients in long‐term real‐world practice are limited. This was a single‐centre, uncontrolled, single‐arm, prospective, observational cohort study that included 254 psoriatic patients treated with secukinumab between September 2019 and December 2022. Demographic and clinical characteristics of patients, clinical response and adverse events were evaluated. The 75% improvement in Psoriasis Area and Severity Index score (PASI 75), PASI 90, and PASI 100 in the 300 mg secukinumab group at 12 weeks were 91.7%, 74.0% and 39.7% respectively, increasing to 94.5%, 74.5% and 47.6% at 52 weeks. High body mass index (BMI), previous exposure to biologic therapies and history of previous conventional systemic therapies were associated with lower rates of PASI response. During the study period, 68 patients reported 83 adverse events (AEs) and the most frequent AEs were eczematous lesions. Up to 14.5% patients withdrew treatment due to disease remission combined with inconvenient transportation during the COVID‐19 pandemic at 52 weeks. The rate of psoriasis exacerbation after COVID‐19 infection in patients treated with secukinumab was 24.3% (17/70). This real‐world study confirmed the high effectiveness of secukinumab in Chinese patients with moderate to severe plaque psoriasis, with an acceptable safety profile.

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalPsoriasisAntibodies, Monoclonal, HumanizedHumansProspective StudiesPandemicsTreatment OutcomeSeverity of Illness IndexChina

Author keywords

effectivenesspsoriasisreal-worldsafetysecukinumab

Substances

secukinumabAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Authors and institutions

  • Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, P. R. China.

ORCID profiles: Chen Yu

Funding

  • National Natural Science Foundation of China

Cite

APA

Zhou, J., Yuan, Y., Liu, Y., Chu, M., Liu, H., Liu, Q., Wang, R., Shao, S., Wang, G., & Yu, C. (2024). Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice. Experimental Dermatology. https://doi.org/10.1111/exd.14890

Vancouver

Zhou J, Yuan Y, Liu Y, Chu M, Liu H, Liu Q, et al. Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice. Experimental Dermatology. 2024. doi:10.1111/exd.14890

BibTeX
@article{Zhou2024,
  author = {Zhou, Jian and Yuan, Yuan and Liu, Yanhua and Chu, Mengyang and Liu, Huan and Liu, Qian and Wang, Rui and Shao, Shuai and Wang, Gang and Yu, Chen},
  title = {Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice},
  journal = {Experimental Dermatology},
  year = {2024},
  doi = {10.1111/exd.14890}
}
Start for free →